Abstract
Enterally-administered nimodipine is the only approved drug formulation available in the United States for treatment of patients with aneurysmal subarachnoid hemorrhage. Intravenous nimodipine is available in other countries but it contains a high concentration of ethanol that is irritating to the vasculature, can alter the effects of other medications, impair neurological assessments and is potentially harmful to the liver. We developed a sterile aqueous solution of nimodipine solubilized in polysorbate 80 micelles (GTX-104) that circumvents these problems. GTX-104 has been administered to 168 healthy human volunteers in 2 studies. We report the second study here, a phase 1, single center, randomized, 2-period cross over study that assessed the pharmacokinetics of GTX-104 and oral nimodipine capsules, which is the reference standard, in 58 healthy human volunteers. GTX-104 was administered for 72 hours as a continuous infusion of 0.15 mg/hour with a 30 minute bolus infusion of 4 mg every 4 hours. Nimodipine capsules were administered orally at a dose of 60 mg every 4 hours for 72 hours. The maximum plasma concentrations after the first dose of each formulation were similar (GTX-104: 63 ng/mL, n=57 versus nimodipine capsules: 69 ng/mL, n=56, ratio and 90% confidence interval [CI] of geometric means: 92% [90% CI: 82-104%]). The areas under the concentration-time curves on the 3rd day at steady state also were the same (GTX-104: 497 ng*h/mL, n=55 versus nimodipine capsules: 495 ng*h/mL, n=56, ratio and 90% CI of geometric means: 106% [90% CI: 99-114%]). The secondary pharmacokinetic parameters (daily maximum concentration at steady-state and time to maximum concentration) were also similar for the 2 formulations. The variability in PK parameters was less for GTX-104 compared to oral nimodipine. The average oral bioavailability for nimodipine capsules was 7%. These results enabled a Phase 3 safety study of GTX-104 in humans with aneurysmal subarachnoid hemorrhage.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov ID NCT05418348 https://clinicaltrials.gov/study/NCT05418348?term=NCT05418348&rank=1
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra IRB is registered with OHRP and FDA under IRB#00000971. The IRB approved the above referenced protocol with the modifications listed below on 17 Aug 2021: ? Modifications to the Informed Consent Form On 20 Aug 2021, the IRB reviewed and approved with modifications, additional revisions to the Informed Consent Form. Additionally, on 20 Aug 2021, the IRB reviewed and approved the Protocol Clarification Letter. All subjects provided consent in writing
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files
